Cellectis S.A.
Cellectis S.A. (CLLS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CLLS · as of Sep 30, 2025
Ownership Breakdown
29
Institutional Holders
▲ 5 vs Q2
$23.69M
Total Inst. Value
▲ $5.83M vs Q2
100.42M
Shares Outstanding
freeFloat 85.30%
8.31M
13F Shares Held
▼ 3.45M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CLLS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
LONG FOCUS CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 4.12M | 4.11% | 4.11% | $11.75B | Nov 14, 2025 | ▼ 594.0K |
B GROUP, INC. biological products, (no diagnostic substances) | 3.28M | 3.27% | 3.27% | $9.35B | Nov 14, 2025 | ▲ 25.0K |
MACQUARIE GROUP LTD biological products, (no diagnostic substances) | 226.9K | 22.61% | 22.61% | $647.00M | Nov 13, 2025 | — held |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 222.0K | 22.12% | 22.12% | $632.58M | Nov 14, 2025 | NEW |
MORGAN STANLEY biological products, (no diagnostic substances) | 87.7K | 8.74% | 8.74% | $249.87M | May 27, 2026 | ▼ 5.1K |
LPL FINANCIAL LLC biological products, (no diagnostic substances) | 85.1K | 8.49% | 8.49% | $242.67M | Nov 12, 2025 | ▼ 515 |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 57.7K | 5.76% | 5.76% | $164.56M | Nov 14, 2025 | ▲ 22.1K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 53.9K | 5.37% | 5.37% | $153.51M | Nov 14, 2025 | ▲ 19.4K |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 52.7K | 5.25% | 5.25% | $150.19M | Nov 14, 2025 | NEW |
BNP PARIBAS ARBITRAGE, SNC biological products, (no diagnostic substances) | 41.3K | 4.12% | 4.12% | $117.70M | Nov 13, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+84.6K shares7
New Positions
first time holders6
Decreased
−623.8K shares3
Sold Out
fully exitedNet shares change (top 50)
539.1K
+84.6K / −623.8K
Net new holders
+5
7 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CLLS insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cellectis S.A. (CLLS) is primarily owned by institutional investors, who hold approximately 8.3% of total shares outstanding. Company insiders own approximately 14.70%, while retail and public investors account for the remaining 77.02%.
The largest institutional shareholder of Cellectis S.A. is LONG FOCUS CAPITAL MANAGEMENT, LLC, holding approximately 4.12 million shares — equal to 4.11% of outstanding shares — as of September 30, 2025.
A total of 29 institutional investors currently hold CLLS stock, with a combined institutional value of approximately $23,687,285 as of the most recent 13F filing period.
Frequently asked questions
CLLS ownershipCellectis S.A. (CLLS) is primarily owned by institutional investors, who hold approximately 8.3% of shares. The largest shareholder is LONG FOCUS CAPITAL MANAGEMENT, LLC with a 4.11% stake. Company insiders hold 14.70%. Data sourced from SEC Form 13F as of September 30, 2025.